Oxford Nanopore sequencing technology has been used to develop a sequencing assay and customised analysis pipeline for the comprehensive and accurate detection of variation at the specific chromosomal location associated with SMA. This finding could make early screening and faster treatment more accessible for SMA, a debilitating genetic disorder characterised by the loss of motor neurons that causes muscle wasting and weakness.
